文献速递胸部肿瘤放疗放疗物理与技术

≥80岁早期非小细胞肺癌单发及多原发灶的立体定向放疗

Stereotactic body radiotherapy for single and multiple early-stage non-small cell lung cancer in patients aged ≥ 80 years.
PubMed 文献 · Radiat Oncol · 2025-07-17

这项回顾性研究纳入118例≥80岁、共141个经SBRT治疗的早期NSCLC原发灶(19例为多原发肺癌),中位随访47个月;2年局部控制率96.2%、5年86.4%,2年癌症特异性生存率88.6%,未观察到>2级毒性,年龄与Charlson合并症指数是OS和PFS的独立预测因素。

要点

  • ≥80岁早期NSCLC及多原发肺癌SBRT的2年局部控制率达96.2%。
  • 5年局部控制率86.4%,5年癌症特异性生存率76.6%。
  • 未观察到>2级毒性,年龄与Charlson合并症指数独立预测OS和PFS。

核心结论

  • SBRT对≥80岁早期NSCLC(含多原发肺癌)有效且安全,局部控制和癌症特异性生存率良好、毒性低。

研究设计与样本

  • 回顾性研究,纳入118例≥80岁患者共141个SBRT治疗的早期NSCLC原发灶,其中19例为多原发肺癌。

主要发现

  • 中位随访47个月(范围3-169个月)。
  • 2年局部控制率96.2%(95%CI 90.1-98.6%),5年86.4%(95%CI 71.8-93.8%)。
  • 2年PFS 67.0%(95%CI 57.4-74.9%)、OS 74.7%(95%CI 65.4-81.1%);5年PFS 24.7%(95%CI 14.5-35.6%)、OS 30.2%(95%CI 19.4-41.7%)。
  • 2年癌症特异性生存率88.6%(95%CI 80.3-93.6%),5年76.6%(95%CI 61.4-86.4%)。
  • 年龄与Charlson合并症指数是OS和PFS的独立预测因素;未观察到>2级毒性。

临床怎么用

  • 对≥80岁、医学上不适合手术或拒绝手术的早期NSCLC患者,SBRT可作为替代治疗选择,包括多原发肺癌。
  • 治疗决策时可结合年龄与Charlson合并症指数评估OS和PFS风险。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer primarily affects elderly individuals and is the leading cause of cancer-related death in people aged 80 years and older. In addition, the incidence of multiple primary lung cancer (MPLC) is increasing worldwide. Although surgery is recommended as the standard of care, many elderly patients are considered medically unsuitable, or they refuse surgery. The role of stereotactic body radiotherapy (SBRT) as an alternative treatment option for these elderly patients, particularly those with multiple primary lung cancer, has not been fully elucidated. Therefore, the aim of this study was to report the outcome and toxicities associated with SBRT for histologically confirmed early-stage non-small cell lung cancer (NSCLC) and synchronous and metachronous multiple primary lung cancer in patients aged ≥ 80 years. METHODS: This retrospective study included 118 patients aged ≥ 80 years with a total of 141 SBRT-treated primary lung cancers (19 patients with MPLC). We assessed local control (LC), progression-free survival (PFS), overall survival (OS) and cancer-specific survival (CSS). We further evaluated toxicities and factors impacting therapeutic efficacy. RESULTS: The median follow-up after SBRT was 47 months (range 3-169 months). The LC rate was 96.2% (95% CI: 90.1 to 98.6%) two years and 86.4% (71.8 to 93.8%) five years after SBRT for NSCLC/MPLC. The PFS and OS rates were 67.0% (57.4 to - 74.9%) and 74.7% (65.4 to - 81.1%), respectively, after two years and 24.7% (14.5 to 35.6%) and 30.2% (19.4 to 41.7%), respectively, after five years. The CSS rate was 88.6% (80.3-93.6%) at two years and 76.6% (61.4-86.4%) at 5 years after SBRT. Age and the Charlson Comorbidity Index score were found to be independent predictors of OS and PFS. Predictors other than these patient-related factors could not be identified. Toxicities higher than Grade 2 after SBRT of NSCLC and MPLC were not observed. CONCLUSION: This study emphasises the efficacy and safety of SBRT in the treatment of early-stage NSCLC in patients aged ≥ 80 years, including those with MPLC. SBRT proves to be an appropriate treatment modality for this frail patient group, as it provides favourable LC and CSS rates with low toxicity.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vorbach SM, Seppi T, Peeken JC, et al. Stereotactic body radiotherapy for single and multiple early-stage non-small cell lung cancer in patients aged ≥ 80 years. Radiat Oncol. 2025. PMID: 40676665. doi:10.1186/s13014-025-02693-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。